Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Leronlimab (PRO 140) is a humanized IgG4,k monoclonal antibody (mAb) that recognizes the C-C
chemokine receptor type 5 (CCR5). Disruption of the C-C chemokine ligand 5 (CCL5)-CCR5 axis
via leronlimab-mediated CCR5 blockade might prevent pulmonary trafficking of pro-inflammatory
leukocytes and dampen pathogenic immune activation in coronavirus disease 2019 (COVID-19).
The purpose of the study is to assess the safety and efficacy of leronlimab plus standard of
care in patients hospitalized with COVID-19 pneumonia who are not requiring mechanical
ventilation or extracorporeal oxygenation (ECMO).